Sign in
0HL9 Stock Price, Chart, Stats & News
Affimed N.V.
Save
Affimed N.V. (0HL9) does not currently pay a dividend.
1,540
Market cap
–
Current P/E
–
Forward P/E
0HL9 chart
About
Health care
Sector
Biotechnology
Industry
Affimed N. V. is a clinical-stage biopharmaceutical company focused on the discovery and development of cancer immunotherapies, with operations spanning the United States, Germany, and the rest of Europe. The company's primary investigational therapy, AFM13, has successfully completed a Phase II clinical study for peripheral T-cell lymphoma.
Similar securities
Based on sector and market capitalization
Report issue